Peptide Half-Life: Why Schedules Differ
Why some peptides are injected daily and others weekly — DPP-4 degradation, albumin binding, and what half-life means for steady state and a missed dose.
Some peptides are administered once a week. Others would be useless at anything less than daily. The difference is almost entirely one number: half-life.
Understanding it explains why dosing schedules look the way they do, why protocols escalate gradually, and why a delayed dose means something different for one compound than for another.
What half-life actually means
Half-life is the time it takes for the concentration of a substance in blood plasma to fall by half. It is not the duration of effect, and it is not how long the substance is detectable — but it governs both.
Two consequences follow from it, and both are practical:
- Reaching steady state takes about four to five half-lives. Until then, each dose is added to a residue that has not yet stabilised, and the average concentration is still climbing.
- Clearing the substance takes about the same. Stopping is not instantaneous for a long-half-life compound.
Why native peptides disappear so fast
The body is built to take peptides apart. They are, structurally, exactly what digestive and plasma proteases exist to cleave.
Native GLP-1 is the standard example. The enzyme DPP-4 (dipeptidyl peptidase-4) cleaves it at the N-terminus, and Deacon and colleagues showed in 1995 that the hormone is degraded within roughly two minutes of reaching the circulation, whether given subcutaneously or intravenously.
Two minutes is not a dosing schedule. It is why the hormone itself was never a drug, and why an entire class of medicines exists to engineer around that fact.
The three ways to extend it
1. Block the cleavage site
If DPP-4 cuts at a specific position, put something there it cannot cut. Semaglutide places Aib — an unnatural amino acid — at position 8, exactly where the enzyme attacks.
2. Bind to albumin
Albumin is the most abundant protein in plasma and is cleared slowly. Attaching a fatty acid side chain that binds it reversibly turns albumin into a reservoir: it holds most of the circulating peptide and releases it gradually. This is the mechanism behind both semaglutide and tirzepatide.
3. Make the molecule bigger
Small molecules are filtered out by the kidney. Increasing effective size — through PEGylation or fusion to a larger protein — slows renal clearance. This approach is used more in protein therapeutics than in the peptides discussed here.
| Compound | Approximate half-life |
|---|---|
| Native GLP-1 | ~2 minutes |
| Tirzepatide | ~5 days |
| Semaglutide | ~1 week |
What this means for a schedule
Escalation is pharmacology, not caution theatre. If steady state arrives after four or five half-lives, then for a weekly compound the concentration is still rising well over a month in. Protocols that step up gradually are tracking that curve.
A delay is not equally forgiving. With a half-life of a week, a dose taken a day late lands on a plasma level that has barely moved. With a half-life of hours, the same delay can mean the concentration has effectively reached zero and the profile restarts.
The interval is part of what was administered. A weekly compound taken every ten days is a different exposure from the same amount taken every seven — the quantity per injection is identical, the average concentration is not.
Half-life figures are population averages from pharmacokinetic studies. Individual clearance varies with kidney and liver function, body weight and other medications. Nothing here is a schedule recommendation — the authority for any specific product is its prescribing information and the prescriber.
Why this makes tracking worth doing
If the interval is part of the exposure, then a schedule remembered approximately is data lost. What is worth having is the actual date and time of each administration, and the gaps as they really were rather than as they were intended.
That is the record PeptCycle keeps: a calendar of what was administered and when, reminders that fire on the schedule you set, and a history you can export — stored locally on the device, with no account and no server.
Frequently asked questions
What does half-life mean?
The time it takes for the concentration of a substance in blood plasma to fall by half. It is the single number that most determines how often something has to be administered.
Why is native GLP-1 useless as a medicine?
Because the enzyme DPP-4 cleaves it at the N-terminus within about two minutes of release. Deacon and colleagues demonstrated this in humans in 1995. Every GLP-1 medicine is an attempt to engineer around that degradation.
How long does it take to reach steady state?
As a general pharmacokinetic rule, roughly four to five half-lives. For a compound with a half-life of about a week that means several weeks — which is why trial protocols escalate gradually instead of starting at the target dose.
Does a missed dose matter more for a short or a long half-life?
More for a short one. With a long half-life a substantial fraction is still circulating a day later, so a delay changes the curve modestly. With a short half-life, the same delay can mean the concentration has effectively reached zero.
Sources
- Deacon C. et al., Both subcutaneously and intravenously administered GLP-1 are rapidly degraded from the NH2-terminus, Diabetes 1995
- Lau J. et al., Discovery of the Once-Weekly GLP-1 Analogue Semaglutide, J Med Chem 2015
- FDA — Mounjaro (tirzepatide) prescribing information
- FDA — Ozempic (semaglutide) prescribing information